September 28, 2022
Out in the Lancet Infectious Diseases, One Health Trust researchers and collaborators are calling for policymakers and funders to include vaccination in AMR mitigation plans as studies continue to highlight the value of vaccines in reducing infections and the need for antibiotic use. The rapid response of vaccine developers to the COVID-19 pandemic shows that the vaccine development process does not need to be lengthy. Upfront funding and greater coordination between clinical trial groups, regulators, and policymakers, can decrease the time to license vaccines. Additionally, new vaccine platforms that have been proven effective will hopefully overcome the difficulties that have impeded bacterial vaccine development in the past.
Find the article here.